Thrivent Financial For Lutherans Lineage Cell Therapeutics, Inc. Transaction History

Thrivent Financial For Lutherans

  • $52.6 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$1.13 - $1.77 $16,950 - $26,550
15,000 New
15,000 $17,000
Q4 2021

Feb 16, 2022
SELL
$1.84 - $2.68 $78,260 - $113,988
-42,533 Closed
0 $0
Q3 2021

Nov 15, 2021
SELL
$2.26 - $2.86 $309 - $391
-137 Reduced 0.32%
42,533 $107,000
Q2 2021

Aug 19, 2021
BUY
$2.17 - $3.0 $92,593 - $128,010
42,670 New
42,670 $121,000

Others Institutions Holding LCTX

# of Institutions
121
Shares Held
94.2M
Call Options Held
63.8K
Put Options Held
1K
View Full List

About Lineage Cell Therapeutics, Inc.

LCTX Quotes by TradingView
  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $109M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Thrivent Financial For Lutherans Portfolio

Follow Thrivent Financial For Lutherans and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email